Contract analysis

I. Description of the Parties A. The Acquiring Person — Ardent Capital Partners III LP Ardent Capital Partners III LP is a Delaware limited partnership formed for the purpose of making private equity investments. Its principal office is located at 399 Park Avenue, 41st Floor, New York, NY 10022. The general partner of Ardent Capital Partners III LP is Ardent Capital GP III LLC, a Delaware limited liability company. T

1. Marlowe Asset Management Rehabilitation Holdings LLC ("Marlowe Asset Management Rehab"). Marlowe Asset Management Rehabilitation Holdings LLC is a Delaware limited liability company headquartered at 8950 Westheimer Road, Suite 600, Houston, TX 77063. Marlowe Asset Management Rehab was acquired by Ardent Capital Partners III LP in April 2022 and has since completed seven add-on acquisitions. Marlowe Asset Managemen

2. Clearpath Diagnostics Inc. ("Clearpath"). Clearpath Diagnostics Inc. is a Delaware corporation headquartered at 1700 Market Street, Suite 3400, Philadelphia, PA 19103. Clearpath was acquired by Ardent Capital Partners III LP in September 2022. Clearpath is an independent clinical laboratory services provider that performs diagnostic testing, including blood work, urinalysis, pathology, and other clinical laborator

II. Relevant Product Markets A proper competitive analysis of the Transaction requires identification of the relevant product markets in which the Parties participate. As demonstrated below, neither Ardent Capital nor any entity within its control participates in the same product markets as Pinnacle. The analysis below first defines the relevant product markets for Pinnacle's operations and then confirms that Ardent

III. Relevant Geographic Markets A. Framework for Geographic Market Definition ASC services and PPM services are inherently local in nature. Patients travel limited distances for outpatient surgical procedures — typically no more than 30 to 45 minutes in urban and suburban markets — and similarly select physicians and physician practices within a relatively circumscribed geographic area. The Commission and the Divisi

IV. Absence of Horizontal Overlap — Detailed Analysis A. Summary Finding The competitive analysis presented in Sections II and III above compels a straightforward and unambiguous conclusion: Ardent Capital and its controlled portfolio companies do not operate any ambulatory surgical centers or physician practice management entities anywhere in the United States. The proposed Transaction is a pure private equity acqui

V. HHI Concentration Analysis A. Methodology. Although the absence of horizontal overlap renders a Herfindahl-Hirschman Index ("HHI") analysis technically unnecessary — a transaction that does not combine competitors produces, by definition, zero incremental concentration — we have nonetheless prepared HHI calculations for the ASC services product market in each of the nine relevant MSAs. We provide this analysis to

VI. Vertical Relationships Analysis A. Identification of Vertical Relationship While the Transaction presents no horizontal competitive concern of any kind, we recognize that a potential vertical relationship exists between one of Ardent Capital's existing portfolio companies — Marlowe Asset Management Rehabilitation Holdings LLC — and Pinnacle Health Systems. We address this vertical relationship proactively and in

VII. Clearpath Diagnostics — No Overlap of Any Kind For the avoidance of doubt, and to address the full scope of Ardent Capital's healthcare portfolio, we confirm that Clearpath Diagnostics Inc. presents no competitive concern of any kind in connection with the Transaction. Clearpath Diagnostics operates exclusively in three states — Pennsylvania, New Jersey, and New York — providing independent clinical laboratory s

VIII. Barriers to Entry and Competitive Conditions A. Certificate of Need (CON) Requirements Several of the states in which Pinnacle operates maintain Certificate of Need programs or analogous licensure restrictions applicable to the establishment or expansion of ambulatory surgical centers. The CON landscape across Pinnacle's nine-state footprint is summarized below: In the six states that maintain CON requirements

IX. Item 4(c) and 4(d) Document Production A. Acquiring Person Documents Ardent Capital Partners III LP, as the Acquiring Person, is producing seven (7) documents responsive to Items 4(c) and 4(d) of the HSR Notification and Report Form. These documents are as follows:

1. Confidential Information Memorandum — Pinnacle Health Systems, Inc. (Project "Summit"), prepared by Crestline Baird & Co. (sell-side financial advisor), dated October 2023 (152 pages).

2. Management Presentation Materials — Pinnacle Health Systems, Inc. (Project "Summit"), prepared by Crestline Baird & Co., dated November 2023 (84 pages).

3. Teaser — Project "Summit," prepared by Crestline Baird & Co., dated September 2023 (6 pages).

4. Ardent Capital Partners III LP — Investment Committee Memorandum: Pinnacle Health Systems, Inc., dated December 15, 2023 (47 pages).

5. Ardent Capital Partners III LP — Supplemental Investment Committee Memorandum: Pinnacle Health Systems, Inc. (Updated for Revised Bid), dated January 12, 2024 (23 pages).

6. Ardent Capital Partners III LP — Limited Partner Advisory Committee Presentation: Pinnacle Health Systems, Inc., dated January 22, 2024 (31 pages).

7. Internal email chain among Ardent Capital investment professionals (Julian Desmond, Priya Chandrasekar, and others), dated November 8–14, 2023, discussing competitive landscape and market dynamics in Pinnacle's operating markets (8 pages). Counsel has reviewed each of these documents in detail. None of these documents identifies any competitive concern associated with the proposed Transaction. The Crestline Baird

1. Four (4) strategic planning presentations prepared by Pinnacle management for the Pinnacle Board of Directors (covering the periods FY 2021, FY 2022, FY 2023, and FY 2024 budget cycle), each discussing Pinnacle's competitive positioning, market share, growth strategy, and competitive landscape in its operating markets.

2. Three (3) sets of Pinnacle Board of Directors meeting minutes containing discussions of competitive positioning, market share trends, and strategic responses to competitor activity (from meetings held in March 2023, June 2023, and September 2023).

3. Two (2) consultant reports on ASC market growth and site-of-service shift trends, prepared by an independent healthcare consulting firm retained by Pinnacle (dated April 2022 and January 2023).

4. Two (2) internal email communications among Pinnacle senior executives discussing competitor activity, including new ASC openings by competitors and competitive responses to payor contracting initiatives (dated August 2023 and November 2023). Counsel has reviewed the Acquired Person's Item 4(c)/4(d) documents in coordination with Greenvale Durneval LLP. None of these documents identifies the proposed Transaction —

X. Conclusion and Request for Early Termination A. Summary of Competitive Analysis Based on the foregoing analysis, we respectfully submit that the proposed acquisition of Pinnacle Health Systems, Inc. by Ardent Capital Partners III LP raises no antitrust concerns and warrants early termination of the HSR Act waiting period. The competitive analysis demonstrates the following:

1. The Transaction is a financial sponsor-to-financial sponsor transfer of a healthcare services platform, in which Veltrano Equity Holdings LLC is selling its controlling interest in Pinnacle to Ardent Capital Partners III LP. This is a change in financial sponsorship, not a combination of competitors.

2. Ardent Capital does not operate any ASCs or PPM entities anywhere in the United States. Neither Ardent Capital Management LLC (as UPE) nor any entity within its control participates in either of the relevant product markets — ASC services or PPM services — in any geographic market.

3. The Transaction produces zero change in HHI in every relevant geographic market. Because Ardent Capital has no pre-existing presence in any relevant product market, the Transaction does not combine market participants and generates no incremental concentration.

4. The only identified relationship between Ardent Capital's existing portfolio and Pinnacle is a competitively insignificant vertical referral pattern between 12 Marlowe Asset Management Rehab physical therapy clinics and co-located or adjacent Pinnacle ASCs in Texas, Florida, and Georgia. This vertical relationship involves less than 2% of Pinnacle's ASC case volume in the affected MSAs, referrals are non-exclusive

5. Clearpath Diagnostics has no geographic or product market overlap with Pinnacle. Clearpath operates exclusively in Pennsylvania, New Jersey, and New York, while Pinnacle operates in nine entirely different states.

6. No theory of competitive harm — horizontal, vertical, or otherwise — is supported by the facts of this Transaction. The Transaction will not substantially lessen competition or tend to create a monopoly in any relevant market.

7. Item 4(c)/4(d) documents produced by both the Acquiring Person and the Acquired Person are consistent with this competitive analysis and do not identify any competitive concern associated with the Transaction. B. Request for Early Termination For the reasons set forth above, Calderwood & Harkness LLP respectfully requests, on behalf of Ardent Capital Partners III LP, that the Bureau of Competition grant early term